Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non–Small Cell Lung Cancer
Valsamo Anagnostou(Johns Hopkins University), Victor E. Velculescu(Johns Hopkins University), Kristen Rodgers(Johns Hopkins University), Julie R. Brahmer(Johns Hopkins University), Edward Gabrielson(Johns Hopkins University), Rachel Karchin(University of Baltimore), Peter B. Illei(Johns Hopkins University), Rohit Bhattacharya(Johns Hopkins University), Jarushka Naidoo(Sidney Kimmel Comprehensive Cancer Center), James R. White(Resphera Biosciences), Christos Georgiades(Johns Hopkins University), Cynthia A. Zahnow(Johns Hopkins University), Violeta Beleva Guthrie(Johns Hopkins University), Stephen B. Baylin(Johns Hopkins University), Patrick M. Forde(Sidney Kimmel Comprehensive Cancer Center), Carolyn Hruban(Johns Hopkins University), Robert B. Scharpf(Johns Hopkins University), Drew M. Pardoll(Bloomberg (United States)), Hyunseok Kang(Johns Hopkins University), Vilmos Adleff(Johns Hopkins University), Jillian Phallen(Johns Hopkins University), Noushin Niknafs(Johns Hopkins University), Qing Kay Li(Johns Hopkins University), Kellie N. Smith(Bloomberg (United States)), William H. Sharfman(Johns Hopkins University), Theresa Zhang(Human Genome Sciences (United States)), Franco Verde(Bloomberg (United States)), Malcolm V. Brock(Johns Hopkins University), Neha Wali(National University of Science and Technology)
Cited by 897
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
|New England Journal of Medicine|2015|9.4k
Cancer Genome Landscapes
|Science|2013|8k
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
|New England Journal of Medicine|2012|8k